09 May, 2018 Nonclinical Safety Evaluation of GalNAc-siRNA Conjugates
We presented a nonclinical safety evaluation of GalNAc-siRNA conjugates at the 8th Annual Biologics Symposium, being held May 8-9, 2018 in Plainsboro, NJ.
These comprehensive nonclinical studies highlight the favorable tolerability profile and wide therapeutic margins for Alnylam’s GalNAc-siRNA conjugate platform.